Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $137.7 million.

  • Adma Biologics' Receivables - Net rose 17457.72% to $137.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.7 million, marking a year-over-year increase of 17457.72%. This contributed to the annual value of $50.0 million for FY2024, which is 8233.84% up from last year.
  • Per Adma Biologics' latest filing, its Receivables - Net stood at $137.7 million for Q3 2025, which was up 17457.72% from $109.7 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Receivables - Net registered a high of $137.7 million during Q3 2025, and its lowest value of $15.4 million during Q1 2021.
  • Moreover, its 5-year median value for Receivables - Net was $28.6 million (2021), whereas its average is $43.0 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first tumbled by 4574.28% in 2022, then soared by 26438.08% in 2025.
  • Adma Biologics' Receivables - Net (Quarter) stood at $28.6 million in 2021, then crashed by 45.74% to $15.5 million in 2022, then soared by 76.85% to $27.4 million in 2023, then surged by 82.34% to $50.0 million in 2024, then skyrocketed by 175.35% to $137.7 million in 2025.
  • Its last three reported values are $137.7 million in Q3 2025, $109.7 million for Q2 2025, and $99.4 million during Q1 2025.